The Effects of a Chinese Herbal Medicine (VGHBPH0) on Patients with Benign Prostatic Hyperplasia: A Pilot Study

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000029126

Enrollment

Unknown

Registered

2020-01-15

Start date

2017-08-07

Completion date

Unknown

Last updated

2020-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign Prostatic Hyperplasia

Interventions

Case series:Chinese herbal medicine (VGHBPH0)

Eligibility

Sex/Gender

Male

Age

40 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Aged > 40 years old; 2. first-line BPH treatments >=3 months; 3. Moderate to severe BPH (IPSS >=8); 4. Stable life signs; 5. Volunteer to join this research.

Exclusion criteria

Exclusion criteria: 1. Gonorrhea or urinary tract infection; 2. Urinary calculi, prostate cancer, bladder tumor and acute/chronic renal failure; 3. Bladder neck fibrosis, interstitial cystitis or urethral stricture; 4. Injured local organs, muscle and nerve caused by pelvic operation or trauma; 5. Upper urinary obstruction and hydrocele combined with damaged renal function; 6. Unable to commit to treatment because of commuting problems to the hospital.

Design outcomes

Primary

Measure	Time frame
International Prostate Symptom Score;	—

Secondary

Measure	Time frame
Aging Male Symptoms;Urine flow;post-voiding residual urine;	—

Countries

China

Contacts

Public ContactTa-Peng Wu

Center for Traditional Medicine, Taipei Veterans General Hospital

tpwu@vghtpe.gov.tw+886 2 2875 7453

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026